These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 32319885)
1. Partial loss of CFIm25 causes learning deficits and aberrant neuronal alternative polyadenylation. Alcott CE; Yalamanchili HK; Ji P; van der Heijden ME; Saltzman A; Elrod N; Lin A; Leng M; Bhatt B; Hao S; Wang Q; Saliba A; Tang J; Malovannaya A; Wagner EJ; Liu Z; Zoghbi HY Elife; 2020 Apr; 9():. PubMed ID: 32319885 [TBL] [Abstract][Full Text] [Related]
2. NUDT21-spanning CNVs lead to neuropsychiatric disease and altered MeCP2 abundance via alternative polyadenylation. Gennarino VA; Alcott CE; Chen CA; Chaudhury A; Gillentine MA; Rosenfeld JA; Parikh S; Wheless JW; Roeder ER; Horovitz DD; Roney EK; Smith JL; Cheung SW; Li W; Neilson JR; Schaaf CP; Zoghbi HY Elife; 2015 Aug; 4():. PubMed ID: 26312503 [TBL] [Abstract][Full Text] [Related]
3. Nudt21 regulates the alternative polyadenylation of Pak1 and is predictive in the prognosis of glioblastoma patients. Chu Y; Elrod N; Wang C; Li L; Chen T; Routh A; Xia Z; Li W; Wagner EJ; Ji P Oncogene; 2019 May; 38(21):4154-4168. PubMed ID: 30705404 [TBL] [Abstract][Full Text] [Related]
4. NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression. Tan S; Li H; Zhang W; Shao Y; Liu Y; Guan H; Wu J; Kang Y; Zhao J; Yu Q; Gu Y; Ding K; Zhang M; Qian W; Zhu Y; Cai H; Chen C; Lobie PE; Zhao X; Sun J; Zhu T Oncogene; 2018 Aug; 37(35):4887-4900. PubMed ID: 29780166 [TBL] [Abstract][Full Text] [Related]
5. The emerging roles of CFIm25 (NUDT21/CPSF5) in human biology and disease. Masamha CP Wiley Interdiscip Rev RNA; 2023; 14(3):e1757. PubMed ID: 35965101 [TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor β1 alters the 3'-UTR of mRNA to promote lung fibrosis. Ko J; Mills T; Huang J; Chen NY; Mertens TCJ; Collum SD; Lee G; Xiang Y; Han L; Zhou Y; Lee CG; Elias JA; Jyothula SSK; Rajagopal K; Karmouty-Quintana H; Blackburn MR J Biol Chem; 2019 Oct; 294(43):15781-15794. PubMed ID: 31488543 [TBL] [Abstract][Full Text] [Related]
7. NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation. Xiong M; Chen L; Zhou L; Ding Y; Kazobinka G; Chen Z; Hou T Theranostics; 2019; 9(24):7156-7167. PubMed ID: 31695759 [No Abstract] [Full Text] [Related]
8. Downregulation of CFIm25 amplifies dermal fibrosis through alternative polyadenylation. Weng T; Huang J; Wagner EJ; Ko J; Wu M; Wareing NE; Xiang Y; Chen NY; Ji P; Molina JG; Volcik KA; Han L; Mayes MD; Blackburn MR; Assassi S J Exp Med; 2020 Feb; 217(2):. PubMed ID: 31757866 [TBL] [Abstract][Full Text] [Related]
9. Downregulation of NUDT21 contributes to cervical cancer progression through alternative polyadenylation. Xing Y; Chen L; Gu H; Yang C; Zhao J; Chen Z; Xiong M; Kazobinka G; Liu Y; Hou T Oncogene; 2021 Mar; 40(11):2051-2064. PubMed ID: 33619322 [TBL] [Abstract][Full Text] [Related]
10. Nudt21 Controls Cell Fate by Connecting Alternative Polyadenylation to Chromatin Signaling. Brumbaugh J; Di Stefano B; Wang X; Borkent M; Forouzmand E; Clowers KJ; Ji F; Schwarz BA; Kalocsay M; Elledge SJ; Chen Y; Sadreyev RI; Gygi SP; Hu G; Shi Y; Hochedlinger K Cell; 2018 Jan; 172(1-2):106-120.e21. PubMed ID: 29249356 [TBL] [Abstract][Full Text] [Related]
11. Suppression of cleavage factor Im 25 promotes the proliferation of lung cancer cells through alternative polyadenylation. Huang J; Weng T; Ko J; Chen NY; Xiang Y; Volcik K; Han L; Blackburn MR; Lu X Biochem Biophys Res Commun; 2018 Sep; 503(2):856-862. PubMed ID: 29928883 [TBL] [Abstract][Full Text] [Related]
12. LINC00921 reduces lung cancer radiosensitivity by destabilizing NUDT21 and driving aberrant MED23 alternative polyadenylation. Zhang N; Liu X; Huang L; Zeng J; Ma C; Han L; Li W; Yu J; Yang M Cell Rep; 2023 Dec; 42(12):113479. PubMed ID: 37999979 [TBL] [Abstract][Full Text] [Related]
13. CFIm25 and alternative polyadenylation: Conflicting roles in cancer. Jafari Najaf Abadi MH; Shafabakhsh R; Asemi Z; Mirzaei HR; Sahebnasagh R; Mirzaei H; Hamblin MR Cancer Lett; 2019 Sep; 459():112-121. PubMed ID: 31181319 [TBL] [Abstract][Full Text] [Related]
14. NUDT21 alters glioma migration through differential alternative polyadenylation of LAMC1. Jonnakuti VS; Ji P; Gao Y; Lin A; Chu Y; Elrod N; Huang KL; Li W; Yalamanchili HK; Wagner EJ J Neurooncol; 2023 Jul; 163(3):623-634. PubMed ID: 37389756 [TBL] [Abstract][Full Text] [Related]
15. Alternative polyadenylation reprogramming of MORC2 induced by NUDT21 loss promotes KIRC carcinogenesis. Tan Y; Zheng T; Su Z; Chen M; Chen S; Zhang R; Wang R; Li K; Na N JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37737260 [TBL] [Abstract][Full Text] [Related]
16. CFIm-mediated alternative polyadenylation remodels cellular signaling and miRNA biogenesis. Ghosh S; Ataman M; Bak M; Börsch A; Schmidt A; Buczak K; Martin G; Dimitriades B; Herrmann CJ; Kanitz A; Zavolan M Nucleic Acids Res; 2022 Apr; 50(6):3096-3114. PubMed ID: 35234914 [TBL] [Abstract][Full Text] [Related]
17. NUDT21 regulates 3'-UTR length and microRNA-mediated gene silencing in hepatocellular carcinoma. Sun M; Ding J; Li D; Yang G; Cheng Z; Zhu Q Cancer Lett; 2017 Dec; 410():158-168. PubMed ID: 28964783 [TBL] [Abstract][Full Text] [Related]
18. Relationship between NUDT21 mediated alternative polyadenylation process and tumor. Xiao S; Gu H; Deng L; Yang X; Qiao D; Zhang X; Zhang T; Yu T Front Oncol; 2023; 13():1052012. PubMed ID: 36816917 [TBL] [Abstract][Full Text] [Related]
19. NUDT21 suppresses the growth of small cell lung cancer by modulating GLS1 splicing. Gao CC; Xu QQ; Xiao FJ; Wang H; Wu CT; Wang LS Biochem Biophys Res Commun; 2020 May; 526(2):431-438. PubMed ID: 32228887 [TBL] [Abstract][Full Text] [Related]
20. Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation. Weng T; Ko J; Masamha CP; Xia Z; Xiang Y; Chen NY; Molina JG; Collum S; Mertens TC; Luo F; Philip K; Davies J; Huang J; Wilson C; Thandavarayan RA; Bruckner BA; Jyothula SS; Volcik KA; Li L; Han L; Li W; Assassi S; Karmouty-Quintana H; Wagner EJ; Blackburn MR J Clin Invest; 2019 May; 129(5):1984-1999. PubMed ID: 30830875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]